Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid

5-azacytidine (AZA) has become standard treatment for patients with higher-risk myelodysplastic syndrome (MDS). Response rate is about 50% and response duration is limited. Histone deactylase (HDAC) inhibitors are attractive partners for epigenetic combination therapy. We treated 24 patients with AZ...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuendgen, Andrea, Bug, Gesine, Ottmann, Oliver G., Haase, Detlef, Schanz, Julie, Hildebrandt, Barbara, Nachtkamp, Kathrin, Neukirchen, Judith, Dienst, Ariane, Haas, Rainer, Germing, Ulrich, Gattermann, Norbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3365387/
https://www.ncbi.nlm.nih.gov/pubmed/22704349
http://dx.doi.org/10.1007/s13148-011-0031-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3365387/
https://www.ncbi.nlm.nih.gov/pubmed/22704349
http://dx.doi.org/10.1007/s13148-011-0031-9

Ejemplares similares